PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsEverolimus
Afinitor(everolimus)
Afinitor, Everolimus, Votubia, Zortress (everolimus) is a small molecule pharmaceutical. Everolimus was first approved as Afinitor on 2009-03-30. It has been approved in Europe to treat breast neoplasms, pancreatic neoplasms, renal cell carcinoma, and tuberous sclerosis. The pharmaceutical is active against serine/threonine-protein kinase mTOR.
Download report
Favorite
Novartis Pharmaceuticals
Drugs Approved for Childhood Cancers
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
nervous system diseasesD009422
urogenital diseasesD000091642
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Trade Name
FDA
EMA
Afinitor, Afinitor disperz, Zortress (generic drugs available since 2018-04-12)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Everolimus
Tradename
Company
Number
Date
Products
ZORTRESSNovartisN-021560 RX2010-04-20
4 products, RLD
AFINITORNovartisN-022334 RX2009-03-30
4 products, RLD
AFINITOR DISPERZNovartisN-203985 RX2012-08-29
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
afinitorNew Drug Application2023-08-01
everolimusANDA2050-01-01
zortressNew Drug Application2023-09-14
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
EVEROLIMUS, AFINITOR DISPERZ, NOVARTIS PHARM
2025-04-10ODE-169
EVEROLIMUS, AFINITOR, NOVARTIS
2023-02-26ODE-108
Patent Expiration
Patent
Expires
Flag
FDA Information
Everolimus, Afinitor, Novartis
90062242028-07-01U-1681
84101312025-11-01U-1368
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EG: Mammalian target of rapamycin (mtor) kinase inhibitors
— L01EG02: Everolimus
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA18: Everolimus
HCPCS
Code
Description
J7527
Everolimus, oral, 0.25 mg
Clinical
Clinical Trials
1142 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324—I25.1121853117191
Breast neoplasmsD001943EFO_0003869C50326314214112
Renal cell carcinomaD002292EFO_0000376—2538751278
NeoplasmsD009369—C80472422977
Coronary diseaseD003327————3102942
Kidney transplantationD016030———51418239
Coronary stenosisD023921EFO_1000882———492639
Neuroendocrine tumorsD018358EFO_1001901D3A.8121373638
Myocardial ischemiaD017202EFO_1001375I20-I25——242430
Acute coronary syndromeD054058EFO_0005672—12391428
Show 49 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney neoplasmsD007680EFO_0003865C645131—321
Prostatic neoplasmsD011471—C619101——17
Tuberous sclerosisD014402HP_0009720Q85.15115——15
Triple negative breast neoplasmsD064726——4101——14
Stomach neoplasmsD013274EFO_0003897C16582——12
Carcinoid tumorD002276—D3A.00352——9
LymphangioleiomyomatosisD018192—J84.81451—18
Ovarian neoplasmsD010051EFO_0003893C56261——7
Large b-cell lymphoma diffuseD016403—C83.3351——7
AstrocytomaD001254EFO_0000271—341——7
Show 17 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C25912——117
Non-small-cell lung carcinomaD002289——143———16
Head and neck neoplasmsD006258——99———14
Neuroendocrine carcinomaD018278——210———11
SarcomaD012509——47———10
Colorectal neoplasmsD015179——58———10
GliomaD005910EFO_0000520—55———10
Hodgkin diseaseD006689—C8176———9
LymphomaD008223—C85.965———9
GlioblastomaD005909EFO_0000515—64———9
Show 114 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228—C85.94————4
Medullary carcinomaD018276——2————2
Salivary gland neoplasmsD012468EFO_0003826D112————2
Tongue neoplasmsD014062EFO_0003871C02.92————2
Verrucous carcinomaD018289——2————2
Hematologic neoplasmsD019337——1————1
Myelomonocytic leukemia chronicD015477—C93.11————1
AnemiaD000740HP_0001903D64.91————1
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.21————1
Myeloid leukemia chronic-phaseD015466——1————1
Show 25 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318HP_0001626—————1313
Heart diseasesD006331EFO_0003777I51.9————66
Arterial occlusive diseasesD001157EFO_0009085—————55
Drug-eluting stentsD054855——————33
Optical coherence tomographyD041623——————33
ArteriosclerosisD001161EFO_0009086I70————33
AngioplastyD017130——————22
Islets of langerhans transplantationD016381——————11
InfarctionD007238EFO_0009463—————11
NecrosisD009336——————11
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEverolimus
INNeverolimus
Description
Everolimus is a macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent. It has a role as an antineoplastic agent, an immunosuppressive agent, a mTOR inhibitor, an anticoronaviral agent and a geroprotector. It is a primary alcohol, a secondary alcohol, an ether, a cyclic ketone, a cyclic acetal and a macrolide lactam. It is functionally related to a member of sirolimus.
Classification
Small molecule
Drug classimmunosuppressives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
Identifiers
PDB—
CAS-ID159351-69-6
RxCUI—
ChEMBL IDCHEMBL1908360
ChEBI ID68478
PubChem CID6442177
DrugBankDB01590
UNII ID9HW64Q8G6G (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Afinitor – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Zortress – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 36,209 documents
View more details
Safety
Black-box Warning
Black-box warning for: Everolimus, Zortress
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
47,149 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use